FIRRM and breast cancer: Function assays, including CCK-8, colony formation and flow cytometry were conducted to assess the impact of C1orf112 on cell proliferation, cycle progression, and apoptosis.<h4>Results</h4>C1orf112 was highly expressed in breast cancer, with bioinformatics and immunohistochemical analysis confirming its upregulation in tumor tissues as its potential as a diagnostic marker.